SCHEMBL2473103

SCHEMBL2473103

COC(=O)C1CCC(Oc2cccc3ccccc23)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.62
RAB9A P51151 1/20 0.62
KMT2A Q03164 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 2/20 0.46
PGR P06401 1/20 0.46
GAA P10253 1/20 0.46
PTGS1 P23219 1/20 0.46
MAPK1 P28482 1/20 0.46
ENPP2 Q13822 6/20 0.45
FABP7 O15540 4/20 0.43
FABP3 P05413 4/20 0.43
FABP5 Q01469 4/20 0.43
KDM4E B2RXH2 3/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3333731 1.00 MEN1 (0.62) MEN1RAB9AKMT2AL3MBTL1ALDH1A1
SCHEMBL3331589 0.82 MEN1 (0.54) MEN1RAB9AKMT2AL3MBTL1ALDH1A1
SCHEMBL2477604 0.82 MEN1 (0.54) MEN1RAB9AKMT2AL3MBTL1ALDH1A1
SCHEMBL16902862 0.82 MEN1 (0.51) MEN1RAB9AKMT2AL3MBTL1ALDH1A1
SCHEMBL2469471 0.81 EPHX2 (0.47) MEN1RAB9AKMT2AL3MBTL1ALDH1A1
SCHEMBL2469475 0.81 EPHX2 (0.47) MEN1RAB9AKMT2AL3MBTL1ALDH1A1
SCHEMBL2473263 0.80 LPAR1 (0.51) MEN1RAB9AKMT2AL3MBTL1ALDH1A1
SCHEMBL2473260 0.80 LPAR1 (0.51) MEN1RAB9AKMT2AL3MBTL1ALDH1A1
SCHEMBL10174501 0.79 SMN1; SMN2 (0.45) ALDH1A1HSD17B10GAAHPGDTSHR
SCHEMBL14936956 0.77 KMT2A (1.00) MEN1RAB9AKMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370441-B1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-09-11 EP disclosed
US-8461152-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2013-06-11 US disclosed
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES SCHNIDER PATRICK (CH) 2012-09-06 US disclosed
US-8227458-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
EP-2370441-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-10-05 EP disclosed
WO-2010060836-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES HOFFMANN-LA ROCHE, INC. 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 MEN1 2012/4885RAB9A 441/4885KMT2A 2850/4885
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 MEN1 2012/4885RAB9A 441/4885KMT2A 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.